Sebastian Leon Vallejo, Perla Karina Anzures-Gómez, César Camacho-Becerra, Daniel Reyes-Ortega, Luis Humberto Torres-Pérez, Gustavo González-González
La relevancia de este caso clínico se sustenta en que el diagnóstico oportuno de enfermedad vascular cerebral se centra en delimitar el daño una vez diagnosticado procurando en todo momento las zonas de oligohemia y penumbra que si bien es un problema de salud pública entre mayor accesibilidad a información sombre manifestaciones clínicas complejas con abordaje de exploración neurológica se podrán brindar más herramientas para los colegas mejorando cada vez más el abordaje terapéutico. Se reporta un caso clínico inusual en cuanto a ictus al igual que se realiza una revisión de la literatura retomando que la arteria de Percherón fue descrita por primera vez en 1973 por Gérard Percherón como una variante anatómica tálamo perforante no tan infrecuente, presente en hasta el 11 al 33% de la población, regularmente subdiagnósticada en nuestro medio, recordando que la irrigación de mesencéfalo anterior e inferior y tálamo es dada por la arteria carótida interna mientras que los territorios mediales, laterales y posteriores son irrigados por el sistema vertebrobasilar. Este síndrome talamopeduncular debido a la oclusión de la arteria de Percherón se expresa como un infarto talámico bilateral medial que generalmente cursa con la triada de alteración del estado del despierto en varios niveles incluso coma, súbita paresia parcial o total de la mirada vertical, afectación de la cognición memoria.
{"title":"Síndrome de la arteria de Percherón, reporte de caso clínico y revisión de la literatura","authors":"Sebastian Leon Vallejo, Perla Karina Anzures-Gómez, César Camacho-Becerra, Daniel Reyes-Ortega, Luis Humberto Torres-Pérez, Gustavo González-González","doi":"10.31157/an.v28i1.379","DOIUrl":"https://doi.org/10.31157/an.v28i1.379","url":null,"abstract":"La relevancia de este caso clínico se sustenta en que el diagnóstico oportuno de enfermedad vascular cerebral se centra en delimitar el daño una vez diagnosticado procurando en todo momento las zonas de oligohemia y penumbra que si bien es un problema de salud pública entre mayor accesibilidad a información sombre manifestaciones clínicas complejas con abordaje de exploración neurológica se podrán brindar más herramientas para los colegas mejorando cada vez más el abordaje terapéutico. \u0000 \u0000Se reporta un caso clínico inusual en cuanto a ictus al igual que se realiza una revisión de la literatura retomando que la arteria de Percherón fue descrita por primera vez en 1973 por Gérard Percherón como una variante anatómica tálamo perforante no tan infrecuente, presente en hasta el 11 al 33% de la población, regularmente subdiagnósticada en nuestro medio, recordando que la irrigación de mesencéfalo anterior e inferior y tálamo es dada por la arteria carótida interna mientras que los territorios mediales, laterales y posteriores son irrigados por el sistema vertebrobasilar. \u0000 \u0000Este síndrome talamopeduncular debido a la oclusión de la arteria de Percherón se expresa como un infarto talámico bilateral medial que generalmente cursa con la triada de alteración del estado del despierto en varios niveles incluso coma, súbita paresia parcial o total de la mirada vertical, afectación de la cognición memoria.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80961914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Schizophrenia (SCZ) is a severe and chronic neurodevelopmental disorder which onset begins in adolescence or early adulthood. Notwithstanding, the brain dysfunction occurs before the disease and involves the NMDA receptor switch from GluN2B to GluN2A at early neonatal period. We have recently postulated memantine (MEM) as an effective experimental treatment, which may have its root on the modulation of NMDA receptor subunit turnover during the postnatal period by preventing glutamatergic hypofunction in the maternal deprivation model of SCZ. Methods: To explore this possibility, here we have evaluated the turn-over of pre and postsynaptic glutamatergic synaptic components by using primary mouse hippocampal neurons during the synaptic formation period. Results: MK801 stimulation prevented the GluN2B to GluN2A molecular switch at 11 days in vitro (DIV). Importantly, vesicular glutamate transporter 2 (VGLUT2) was also reduced at this time point. MEM treatment reverted these effects by normalizing GluN2B, GluN2A and overexpressing VGLUT2 expression. Conclusion: Our data supports a mechanism by which behavioral abnormalities previously observed in animals after maternal deprivation may be prevented by MEM treatment by regulation of the glutamatergic synaptic molecular composition.
{"title":"The effects of Memantine and MK801 on NMDA receptor switching 2B and 2A subunits in hippocampal cell culture.","authors":"E. Uribe, E. Sanchez-Mendoza","doi":"10.31157/an.v28i2.410","DOIUrl":"https://doi.org/10.31157/an.v28i2.410","url":null,"abstract":"Background: Schizophrenia (SCZ) is a severe and chronic neurodevelopmental disorder which onset begins in adolescence or early adulthood. Notwithstanding, the brain dysfunction occurs before the disease and involves the NMDA receptor switch from GluN2B to GluN2A at early neonatal period. We have recently postulated memantine (MEM) as an effective experimental treatment, which may have its root on the modulation of NMDA receptor subunit turnover during the postnatal period by preventing glutamatergic hypofunction in the maternal deprivation model of SCZ. Methods: To explore this possibility, here we have evaluated the turn-over of pre and postsynaptic glutamatergic synaptic components by using primary mouse hippocampal neurons during the synaptic formation period. Results: MK801 stimulation prevented the GluN2B to GluN2A molecular switch at 11 days in vitro (DIV). Importantly, vesicular glutamate transporter 2 (VGLUT2) was also reduced at this time point. MEM treatment reverted these effects by normalizing GluN2B, GluN2A and overexpressing VGLUT2 expression. Conclusion: Our data supports a mechanism by which behavioral abnormalities previously observed in animals after maternal deprivation may be prevented by MEM treatment by regulation of the glutamatergic synaptic molecular composition.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84242757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alejandro Díaz-Barba, R. Guerrero-Alba, J. Quintanar, Bruno A. Marichal Cancino
The function of the protein-coupled receptor 35 (GPR35) in the central nervous system (CNS) remains largely unknown. Due to its expression in the ventral striatum, a key area in the brain reward system, the function of GPR35 in reinforcing actions is questioning. To analyze if activation of GPR35 in the ventral striatum is related to reinforcing actions, male Wistar rats (250-300 g) received stereotaxic surgery from placing guide cannulae in the ventral striatum. Different doses of lodoxamide (a full rat-GPR35 agonist) or vehicle (DMSO 10%) were injected (intra-ventral-striatum) in the absence and during the pretreatment with ML-194 (a selective GPR35 antagonist). Lodoxamide (100 pmol) induced a significant increment in preference for the drug-conditioning chamber (p < 0.05), but not vehicle or ML-194 per se (p > 0.05). On the other hand, the pretreatment with ML-194 did not prevent lodoxamide's reinforcing effects. Thus, the reinforcing actions of lodoxamide (intra-ventral-striatum) involve mechanisms likely independent of GPR35.
{"title":"Intra-striatum lodoxamide produced conditioning place preference in rats via GPR35 independent mechanisms","authors":"Alejandro Díaz-Barba, R. Guerrero-Alba, J. Quintanar, Bruno A. Marichal Cancino","doi":"10.31157/an.v28i1.382","DOIUrl":"https://doi.org/10.31157/an.v28i1.382","url":null,"abstract":"The function of the protein-coupled receptor 35 (GPR35) in the central nervous system (CNS) remains largely unknown. Due to its expression in the ventral striatum, a key area in the brain reward system, the function of GPR35 in reinforcing actions is questioning. To analyze if activation of GPR35 in the ventral striatum is related to reinforcing actions, male Wistar rats (250-300 g) received stereotaxic surgery from placing guide cannulae in the ventral striatum. Different doses of lodoxamide (a full rat-GPR35 agonist) or vehicle (DMSO 10%) were injected (intra-ventral-striatum) in the absence and during the pretreatment with ML-194 (a selective GPR35 antagonist). Lodoxamide (100 pmol) induced a significant increment in preference for the drug-conditioning chamber (p < 0.05), but not vehicle or ML-194 per se (p > 0.05). On the other hand, the pretreatment with ML-194 did not prevent lodoxamide's reinforcing effects. Thus, the reinforcing actions of lodoxamide (intra-ventral-striatum) involve mechanisms likely independent of GPR35.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89077373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-20DOI: 10.31157/an.v1iinpress.374
J. D. J. Vidal-Mayo, Uriel Guzmán Ramírez, Thierry Hernández-Gilsoul, Ashuin Kammar-García, Ayari Pérez Méndez, Javier Mancilla-Galindo
Antecedentes. El estado epiléptico (EE) es una emergencia médica caracterizada por actividad epiléptica continua o recurrente con una alta mortalidad. La escala STESS (Status Epilepticus Severity Score) permite evaluar el pronóstico de pacientes con EE. Objetivo. Describir las características clínicas de los pacientes con EE en nuestro centro, determinar las variables asociadas a mortalidad y determinar la capacidad predictora de la escala STESS para mortalidad intrahospitalaria. Material y métodos. Estudio de cohorte retrospectivo. Se incluyeron pacientes con diagnóstico de EE durante el periodo de 2000-2020. Se aplicó la escala pronóstica STESS a todos los pacientes. Se obtuvieron datos de las características clínicas y mortalidad intrahospitalaria. Se aplicó un análisis de regresión de Cox para determinar el riesgo de mortalidad por cada punto de la escala STESS, y se calculó el área bajo la curva ROC para determinar la capacidad de discriminación de la escala. Resultados. Fueron incluidos 60 pacientes. La presentación clínica predominante fue el EE convulsivo generalizado en 51.7%, las etiologías más frecuentes fueron sintomáticas agudas (46.7%). La mortalidad hospitalaria fue 40%. El riesgo de mortalidad se incrementa un 38% por cada punto de STESS (B=0.38, HR=1.48, IC95%:1.13-1.94, p=0.005). El área bajo la curva ROC de la escala STESS fue 0.72 con un punto de corte óptimo ≥3 puntos para discriminación de mortalidad hospitalaria. Conclusiones. La escala STESS se asocia significativamente con la mortalidad intrahospitalaria y puede ser usada como predictor de los desenlaces adversos en pacientes con EE.
{"title":"Evaluación de la escala Status Epilepticus Severity Score (STESS) como predictor de la mortalidad intrahospitalaria en pacientes con estado: Estudio observacional retrospectivo","authors":"J. D. J. Vidal-Mayo, Uriel Guzmán Ramírez, Thierry Hernández-Gilsoul, Ashuin Kammar-García, Ayari Pérez Méndez, Javier Mancilla-Galindo","doi":"10.31157/an.v1iinpress.374","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.374","url":null,"abstract":"Antecedentes. El estado epiléptico (EE) es una emergencia médica caracterizada por actividad epiléptica continua o recurrente con una alta mortalidad. La escala STESS (Status Epilepticus Severity Score) permite evaluar el pronóstico de pacientes con EE. \u0000Objetivo. Describir las características clínicas de los pacientes con EE en nuestro centro, determinar las variables asociadas a mortalidad y determinar la capacidad predictora de la escala STESS para mortalidad intrahospitalaria. \u0000Material y métodos. Estudio de cohorte retrospectivo. Se incluyeron pacientes con diagnóstico de EE durante el periodo de 2000-2020. Se aplicó la escala pronóstica STESS a todos los pacientes. Se obtuvieron datos de las características clínicas y mortalidad intrahospitalaria. Se aplicó un análisis de regresión de Cox para determinar el riesgo de mortalidad por cada punto de la escala STESS, y se calculó el área bajo la curva ROC para determinar la capacidad de discriminación de la escala. \u0000Resultados. Fueron incluidos 60 pacientes. La presentación clínica predominante fue el EE convulsivo generalizado en 51.7%, las etiologías más frecuentes fueron sintomáticas agudas (46.7%). La mortalidad hospitalaria fue 40%. El riesgo de mortalidad se incrementa un 38% por cada punto de STESS (B=0.38, HR=1.48, IC95%:1.13-1.94, p=0.005). El área bajo la curva ROC de la escala STESS fue 0.72 con un punto de corte óptimo ≥3 puntos para discriminación de mortalidad hospitalaria. \u0000Conclusiones. La escala STESS se asocia significativamente con la mortalidad intrahospitalaria y puede ser usada como predictor de los desenlaces adversos en pacientes con EE.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"296 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89226367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-17DOI: 10.31157/an.v1iinpress.389
Julio Cesar Villalobos-Comas, E. Castillo-Tamara, Juan Manuel Montaño Lozada, Sandra Marcela Cardona Moica
The novel coronavirus SARS-CoV-2 has caused the death of more than 5 million of people worldwide. Vaccination is the best strategy for controlling the pandemic with an estimated of more that 4 million of people completely vaccinated. The reported adverse events secondary to vaccines against SARS-CoV-2 are mainly mild and moderate, however, there are raising concerns about more severe and long-term outcomes, as well as neurological complications due to the vaccine. We present two cases of psychogenic non epileptiform seizures (PNES) in Colombian female patients, following vaccination against Covid-19. There is no evidence of similar adverse reactions reported on the literature and thus, we decided to report these events in order to help clinicians in recognizing early and properly all the possible neurological manifestations related to this novel approach, that aimes to eradicate the viruses which has come along with worldwide devastating consequences in terms of health and social issues.
{"title":"PSYCHOGENIC NONEPILEPTIC SEIZURES FOLLOWING COVID 19 VACCINE: A REPORT OF TWO CASES IN COLOMBIA","authors":"Julio Cesar Villalobos-Comas, E. Castillo-Tamara, Juan Manuel Montaño Lozada, Sandra Marcela Cardona Moica","doi":"10.31157/an.v1iinpress.389","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.389","url":null,"abstract":"The novel coronavirus SARS-CoV-2 has caused the death of more than 5 million of people worldwide. Vaccination is the best strategy for controlling the pandemic with an estimated of more that 4 million of people completely vaccinated. The reported adverse events secondary to vaccines against SARS-CoV-2 are mainly mild and moderate, however, there are raising concerns about more severe and long-term outcomes, as well as neurological complications due to the vaccine. \u0000We present two cases of psychogenic non epileptiform seizures (PNES) in Colombian female patients, following vaccination against Covid-19. There is no evidence of similar adverse reactions reported on the literature and thus, we decided to report these events in order to help clinicians in recognizing early and properly all the possible neurological manifestations related to this novel approach, that aimes to eradicate the viruses which has come along with worldwide devastating consequences in terms of health and social issues.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82068267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-08DOI: 10.31157/an.v1iinpress.403
E. S. Vargas-Cañas, Eunice Martínez-Jiménez, JA Galnares-Olalde, Francisca Fernández-Valverde, Adib Jorge de Saráchaga, Anna Lisette Bazán-Rodríguez, E. Benítez-Alonso, J. López-Hernández
Antecedentes: las miopatías genéticas en el adulto son infrecuentes y representan un reto diagnóstico. Con el advenimiento de paneles de secuenciación de siguiente generación, se han catalogado molecularmente estas enfermedades, permitiendo un mejor abordaje, seguimiento, pronóstico y tratamiento. Objetivo: describir la frecuencia de los principales fenotipos clínicos de miopatía de origen genético en adultos en un centro de tercer nivel en México. Metodología: se realizó un estudio transversal, se incluyeron a todos los pacientes con diagnóstico clínico de miopatía genética de una clínica de enfermedades neuromusculares del 2017 a 2021. Se recabaron características clínicas y paraclínicas al momento del diagnóstico, reporte de biopsia muscular y estudio genético. Resultados: se incluyeron 85 pacientes. La media de edad de inicio de síntomas fue a los 27, con un retraso en el diagnóstico de 7 años. Los principales fenotipos clínicos son: distrofia de cinturas (28%), distrofia miotónica tipo 1 (26.8%), miopatía congénita (17.1%), miopatía metabólica (9.8%), oculofaríngea (7.3%) y facioescapulohumeral (6.1%). Conclusión: las principales miopatías de origen genético en nuestra población son la distrofia miotónica tipo 1 y la distrofia de cinturas. El reconocimiento de ellas es importante para la apropiada consejería, seguimiento, pronóstico y tratamiento de potenciales condiciones asociadas.
{"title":"Miopatías genéticas en adultos: experiencia de un centro de tercer nivel en México.","authors":"E. S. Vargas-Cañas, Eunice Martínez-Jiménez, JA Galnares-Olalde, Francisca Fernández-Valverde, Adib Jorge de Saráchaga, Anna Lisette Bazán-Rodríguez, E. Benítez-Alonso, J. López-Hernández","doi":"10.31157/an.v1iinpress.403","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.403","url":null,"abstract":"Antecedentes: las miopatías genéticas en el adulto son infrecuentes y representan un reto diagnóstico. Con el advenimiento de paneles de secuenciación de siguiente generación, se han catalogado molecularmente estas enfermedades, permitiendo un mejor abordaje, seguimiento, pronóstico y tratamiento. \u0000Objetivo: describir la frecuencia de los principales fenotipos clínicos de miopatía de origen genético en adultos en un centro de tercer nivel en México. \u0000Metodología: se realizó un estudio transversal, se incluyeron a todos los pacientes con diagnóstico clínico de miopatía genética de una clínica de enfermedades neuromusculares del 2017 a 2021. Se recabaron características clínicas y paraclínicas al momento del diagnóstico, reporte de biopsia muscular y estudio genético. \u0000Resultados: se incluyeron 85 pacientes. La media de edad de inicio de síntomas fue a los 27, con un retraso en el diagnóstico de 7 años. Los principales fenotipos clínicos son: distrofia de cinturas (28%), distrofia miotónica tipo 1 (26.8%), miopatía congénita (17.1%), miopatía metabólica (9.8%), oculofaríngea (7.3%) y facioescapulohumeral (6.1%). \u0000Conclusión: las principales miopatías de origen genético en nuestra población son la distrofia miotónica tipo 1 y la distrofia de cinturas. El reconocimiento de ellas es importante para la apropiada consejería, seguimiento, pronóstico y tratamiento de potenciales condiciones asociadas. \u0000 ","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73900800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-07DOI: 10.31157/an.v1iinpress.411
J. Ramírez-Bermúdez, J. Galnares-Olalde, Alexis García-Sarreón, Karla Rodríguez-Jiménez, Sara Mireles, Victoria Martínez-Ángeles, N. Kerik-Rotenberg, Iván Meneses-Díaz, E. A. Cortés-Mancera, Fabio Andrés Sinisterra-Solis, E. S. Vargas-Cañas, J. C. López-Hernández
Abstract: Background: Brain 18 FDG PET is very useful in the diagnosis of autoimmune encephalitides against post-synaptic receptors. However, little is known about the metabolic changes in other autoimmune encephalitides, such as Bickerstaff stem encephalitis (BBE). Objective: to report the case of a patient with BBE with an 18 FDG PET study and to review the literature. Results: A 20-year-old man with no relevant history presented to the emergency department due to a clinical picture of 7 days of evolution, characterized by non-painful distal paresthesias in the 4 extremities, diplopia, instability on gait and dysphagia. On the day of his hospital stay, he presented alterations in his awake state. The clinical diagnosis of Bikerstaff's stem encephalitis was made. In his paraclinical tests, the cerebrospinal fluid was normal. He received treatment with human immunoglobulin (2 grams/kg) for 5 days. An 18 FDG PET study reported hypermetabolism in the putamen and bilateral caudate nucleus and bilateral occipital hypometabolism. Conclusion: brain 18-FDG PET may be a subrogate marker for understanding CNS compromise in BBE.
摘要:背景:脑18 FDG PET在诊断抗突触后受体的自身免疫性脑肽方面非常有用。然而，对其他自身免疫性脑炎的代谢变化知之甚少，如比克斯塔夫干性脑炎(BBE)。目的:报告一例BBE患者的18 FDG PET检查并复习文献。结果:一名20岁男性，无相关病史，因临床表现为7天进化，以4肢非疼痛性远端感觉异常、复视、步态不稳和吞咽困难为特征。在他住院的那天，他表现出清醒状态的变化。对Bikerstaff干性脑炎进行临床诊断。在他的临床检查中脑脊液是正常的给予人免疫球蛋白(2 g /kg)治疗5天。一项18 FDG PET研究报告了壳核和双侧尾状核的高代谢和双侧枕部的低代谢。结论:脑18-FDG PET可作为了解脑脊髓炎患者中枢神经系统损伤的替代标志物。
{"title":"Is there an autoimmune encephalitis-like brain metabolism pattern in patients with Bickerstaff brainstem encephalitis?","authors":"J. Ramírez-Bermúdez, J. Galnares-Olalde, Alexis García-Sarreón, Karla Rodríguez-Jiménez, Sara Mireles, Victoria Martínez-Ángeles, N. Kerik-Rotenberg, Iván Meneses-Díaz, E. A. Cortés-Mancera, Fabio Andrés Sinisterra-Solis, E. S. Vargas-Cañas, J. C. López-Hernández","doi":"10.31157/an.v1iinpress.411","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.411","url":null,"abstract":"Abstract: \u0000Background: Brain 18 FDG PET is very useful in the diagnosis of autoimmune encephalitides against post-synaptic receptors. However, little is known about the metabolic changes in other autoimmune encephalitides, such as Bickerstaff stem encephalitis (BBE). \u0000Objective: to report the case of a patient with BBE with an 18 FDG PET study and to review the literature. \u0000Results: A 20-year-old man with no relevant history presented to the emergency department due to a clinical picture of 7 days of evolution, characterized by non-painful distal paresthesias in the 4 extremities, diplopia, instability on gait and dysphagia. On the day of his hospital stay, he presented alterations in his awake state. The clinical diagnosis of Bikerstaff's stem encephalitis was made. In his paraclinical tests, the cerebrospinal fluid was normal. He received treatment with human immunoglobulin (2 grams/kg) for 5 days. An 18 FDG PET study reported hypermetabolism in the putamen and bilateral caudate nucleus and bilateral occipital hypometabolism. \u0000Conclusion: brain 18-FDG PET may be a subrogate marker for understanding CNS compromise in BBE.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"185 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72706985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-22DOI: 10.31157/an.v1iinpress.363
Renato García-González, H. Sandoval, Rakesh Mishra, Antonio Malvaso, C. Alarcon-Ruiz, C. Ríos, I. Pérez-Neri
Drug-resistant epilepsy is defined as “the failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules”, 30-40% of the patients with epilepsy present this condition decreasing their quality-of-life and increasing mortality risk. Current literature suggests therapeutic alternatives such as surgery or neurostimulation, but they show some limitations. Unless degenerative progression is prevented and the regulatory role of interneurons is restored, patients with drug-resistant epilepsy may not reach seizure freedom. Ongoing studies have developed techniques to manoeuvre signalling pathways for neural regeneration in the central nervous system, this is defined as “the regrowth or repair of nervous tissues, cells or cell products”. This scoping review protocol aims to evaluate the therapeutic potential of modulating nerve regeneration pathways for patients with drug-resistant epilepsy. Published studies (all publication types) will be retrieved from Web of Science, PubMed, Scopus, EBSCOhost, Ovid, and Google Scholar, from database inception to present. Studies describing patients or experimental models of drug-resistant epilepsy receiving any treatment modulating nerve regeneration pathways will be included. Studies in languages different than Spanish or English that could not be appropriately translated or whose full-text files could not be retrieved after all efforts made will be excluded. Studies will be assessed for eligibility by two independent researchers. Results will be presented in tables. A narrative synthesis will be provided.
耐药癫痫被定义为“对两种耐受、适当选择和使用的抗癫痫药物方案进行充分试验失败”，30-40%的癫痫患者出现这种情况，降低了他们的生活质量，增加了死亡风险。目前的文献建议采用手术或神经刺激等治疗方法，但这些方法有一定的局限性。除非防止退行性进展和恢复中间神经元的调节作用，否则耐药癫痫患者可能无法达到癫痫发作自由。正在进行的研究已经开发出操纵中枢神经系统神经再生信号通路的技术，这被定义为“神经组织、细胞或细胞产物的再生或修复”。这项范围审查方案旨在评估调节神经再生途径对耐药癫痫患者的治疗潜力。已发表的研究(所有出版类型)将从Web of Science, PubMed, Scopus, EBSCOhost, Ovid和Google Scholar中检索，从数据库建立到现在。将包括描述接受任何调节神经再生途径治疗的耐药癫痫患者或实验模型的研究。除西班牙文或英文以外的其他语文的研究，如无法适当翻译，或在作出一切努力后仍无法检索其全文文件，将被排除在外。研究的资格将由两名独立研究人员进行评估。结果将以表格形式呈现。将提供叙述综合。
{"title":"Mechanisms of nerve regeneration for drug-resistant epilepsy: scoping review protocol","authors":"Renato García-González, H. Sandoval, Rakesh Mishra, Antonio Malvaso, C. Alarcon-Ruiz, C. Ríos, I. Pérez-Neri","doi":"10.31157/an.v1iinpress.363","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.363","url":null,"abstract":"Drug-resistant epilepsy is defined as “the failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules”, 30-40% of the patients with epilepsy present this condition decreasing their quality-of-life and increasing mortality risk. Current literature suggests therapeutic alternatives such as surgery or neurostimulation, but they show some limitations. Unless degenerative progression is prevented and the regulatory role of interneurons is restored, patients with drug-resistant epilepsy may not reach seizure freedom. Ongoing studies have developed techniques to manoeuvre signalling pathways for neural regeneration in the central nervous system, this is defined as “the regrowth or repair of nervous tissues, cells or cell products”. This scoping review protocol aims to evaluate the therapeutic potential of modulating nerve regeneration pathways for patients with drug-resistant epilepsy. Published studies (all publication types) will be retrieved from Web of Science, PubMed, Scopus, EBSCOhost, Ovid, and Google Scholar, from database inception to present. Studies describing patients or experimental models of drug-resistant epilepsy receiving any treatment modulating nerve regeneration pathways will be included. Studies in languages different than Spanish or English that could not be appropriately translated or whose full-text files could not be retrieved after all efforts made will be excluded. Studies will be assessed for eligibility by two independent researchers. Results will be presented in tables. A narrative synthesis will be provided.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"242 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76561723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-21DOI: 10.31157/an.v1iinpress.377
L. Moscote-Salazar
{"title":"Meet the Editor: Luis Rafael Moscote-Salazar","authors":"L. Moscote-Salazar","doi":"10.31157/an.v1iinpress.377","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.377","url":null,"abstract":"","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"156 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86315761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：